Targeting Trafficking in Drug Development

<div>Preface</div><div>1. Intracellular trafficking of gonadotropin receptors in health and disease. (Ulloa-Aguirre et al)</div><div>2. Investigating internalization and intracellular trafficking of GPCRs. (Simon R. Foster and Hans Bräuner-Osborne)&nbsp;</div><div>3. Pharmacological chaperones as potential therapeutic strategies for misfolded mutant vasopressin receptors. (Bernard Mouillac and Christiane Mendre)</div><div>4. Targeting of disordered proteins by small molecules in neurodegenerative diseases. (Francesca Longhena, PierFranco Spano, Arianna Bellucci</div><div>5. Pharmacoperones for misfolded gonadotropin receptors. (Claire L. Newton and Ross C. Anderson)</div><div>6. Pharmacological chaperones: Beyond conformational disorders. (Nancy J. Leidenheimer)</div><div>7. Natural (and unnatural) small molecules as pharmacological chaperones and inhibitors in cancer. Isabel Betancor, (David J. Timson, Eduardo Salido, Angel L. Pey)</div><div>8. Heritable skeletal disorders arising from defects in processing and transport of Type I procollagen from the ER: perspectives on possible therapeutic approaches. (Meritxell B. Cutrona, Niamh E. Morgan, Jeremy C. Simpson)</div><div>9. Conserved oligomeric Golgi and neuronal vesicular trafficking. (Leslie K. Climer, Rachel D. Hendrix, Vladimir V. Lupashin)</div><div>10. SLC6 transporter folding diseases and pharmacochaperoning. (Michael Freissmuth, Thomas Stockner, Sonja Sucic)</div><div>11. The molecular physiopathogenesis of islet amyloidosis. (Diti Chatterjee Bhowmick, Sanghamitra Singh, Saurabh Trikha, Aleksandar M. Jeremic)</div><div>12. Folding defects leading to primary hyperoxaluria. (Elisa Oppici, Mirco Dindo, Carolina Conter, Carla Borri Voltattorni, Barbara Cellini)</div><div>13. Potential pharmacological chaperones for cystathionine beta-synthase-deficient homocystinuria. (Tomas Majtan, Angel L. Pey, Paula Gimenez-Mascarell, Luis Alfonso Martínez-Cruz, Csaba Szabo, Victo Kosich, Jan P. Kraus)</div>